Breast cancer

October 19, 2020
TMIST accrual bar graph

TMIST Breast Cancer Screening Trial Rebounds from COVID-19 Shutdown of Cancer Screenings

October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
September 14, 2020
PrECOG logo

Trial Results: PALbociclib CoLlaborative Adjuvant Study (PALLAS)

A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
September 14, 2020
Ingrid Mayer, MD

Trial Spotlight: Ingrid Mayer on Study EA1131 for Triple-Negative Breast Cancer, Including Men

This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively
June 10, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, June 2020

Strong EA research presence at ASCO 2020; the horrific killing of George Floyd; health equity and diversity in the field of oncology; the need for EA to participate in changing a specifically anti-racist culture and increase diversity and inclusion
June 10, 2020
E2112 video image

Trial Results: E2112 Finds No Significant Overall Survival Benefit With Entinostat/Exemestane in Advanced Breast Cancer

The study results, as well as correlative analyses, will be reported in an upcoming medical meeting
June 10, 2020

The Value of TMIST Compared to Other Breast Cancer Screening Studies

TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
May 29, 2020
Doctor patient CT scan

Now Enrolling: FEATURE (EA1183) – FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer

April 15, 2020
Patient in office

Now Enrolling: EA1181 Decreasing Chemotherapy in HER2 Positive Breast Cancer

For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
January 14, 2020
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, December 2019/January 2020

Reflecting on key milestones in 2019: TMIST breast cancer screening trial continues to ramp up; NCORP grant renewal emphasizes screening, symptom control, and cancer care delivery research; new role for Dr. Al Benson; E1912's practice-changing trial results; update on Dr. Otis Brawley's efforts to form the Social Determinants of Health Working Group; EA launches the Comis Symposium
January 13, 2020

Now Enrolling: EAZ171 Trial to Lessen Neuropathy in African American Breast Cancer Patients

November 1, 2019

San Antonio Breast Cancer Symposium Honors EA Vice Chair Joseph A. Sparano

A career distinguished by leadership, collaboration, and practice-changing achievements in clinical and translational breast cancer research that have improved the lives of patients